静脉-静脉体外膜氧合治疗急性呼吸窘迫综合征:系统评价与荟萃分析
该系统评价与荟萃分析纳入5项研究(2项随机对照试验和3项采用匹配技术的观察性研究,总样本量773例),比较成人急性呼吸窘迫综合征患者接受静脉-静脉体外膜氧合与常规机械通气的效果。主要分析纳入2项随机对照试验共429例患者,静脉-静脉体外膜氧合组60天死亡率为34%(73/214),对照组为47%(101/215),风险比0.73(95%CI 0.58-0.92),P=0.008,异质性I²=0%。该结局的GRADE证据等级为中等。3项研究报告了体外膜氧合组大出血发生率,251例中48例(19%)发生大出血。作者认为,在提供静脉-静脉体外膜氧合的中心,这些发现对重度急性呼吸窘迫综合征的管理决策有重要意义。
要点
- 2项随机对照试验共429例成人重度急性呼吸窘迫综合征患者,静脉-静脉体外膜氧合组60天死亡率34%(73/214) vs 对照组47%(101/215),RR 0.73(95%CI 0.58-0.92),P=0.008,I²=0%。
- 该60天死亡率结局的GRADE证据等级为中等。
- 3项研究报告体外膜氧合组大出血发生率:251例中48例(19%)发生大出血。
- 作者认为,与常规机械通气相比,成人重度急性呼吸窘迫综合征使用静脉-静脉体外膜氧合与60天死亡率降低相关,但也与大出血的中度风险相关。
适用人群与场景
- 成人急性呼吸窘迫综合征患者,比较常规机械通气联合或不联合静脉-静脉体外膜氧合。
研究设计与关键结果
- 系统评价与荟萃分析,纳入5项研究(2项随机对照试验和3项采用匹配技术的观察性研究),总样本量773例患者。
- 主要分析纳入2项随机对照试验共429例患者,静脉-静脉体外膜氧合组60天死亡率34%(73/214) vs 对照组47%(101/215),RR 0.73(95%CI 0.58-0.92),P=0.008,I²=0%。
- 3项研究报告体外膜氧合组大出血发生率:251例中48例(19%)发生大出血。
- 该60天死亡率结局的GRADE证据等级为中等。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机对照试验和观察性研究,采用GRADE指南评级。
- 60天死亡率结局的GRADE证据等级为中等。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与常规机械通气相比,成人重度急性呼吸窘迫综合征使用静脉-静脉体外膜氧合与60天死亡率降低相关,但也与大出血的中度风险相关。
- 作者认为,这些发现对提供静脉-静脉体外膜氧合的中心在重度急性呼吸窘迫综合征管理决策方面有重要意义。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Use of extracorporeal membrane oxygenation (ECMO) in adults with severe acute respiratory distress syndrome has increased in the past 10 years. However, the efficacy of venovenous ECMO in people with acute respiratory distress syndrome is uncertain according to the most recent data. We aimed to estimate the effect of venovenous ECMO on mortality from acute respiratory distress syndrome.
METHODS: In this systematic review and meta-analysis, we searched MEDLINE (including MEDLINE In-Process and Epub Ahead of Print), Embase and the Wiley search platform in the Cochrane database for randomised controlled trials and observational studies with matching of conventional mechanical ventilation with and without venovenous ECMO in adults with acute respiratory distress syndrome. Titles, abstracts, and full-text articles were screened in duplicate by two investigators. Data for study design, patient characteristics, interventions, and study outcomes were abstracted independently and in duplicate. Studies were weighted with the inverse variance method and data were pooled via random-effects modelling. We calculated risk ratios (RRs) and 95% CIs to summarise results. The primary outcome was 60-day mortality across randomised controlled trials. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines were used to rate the quality of evidence FINDINGS: We included five studies, two randomised controlled trials and three observational studies with matching techniques (total N=773 patients). In the primary analysis, which included two randomised controlled trials with a total population of 429 patients, 60-day mortality was significantly lower in the venovenous ECMO group than in the control group (73 [34%] of 214 vs 101 [47%] of 215; RR 0·73 [95% CI 0·58-0·92]; p=0·008; I2 0%). The GRADE level of evidence for this outcome was moderate. Three studies included data for the incidence of major haemorrhage in the ECMO group. 48 (19%) of the 251 patients in these three studies had major haemorrhages.
INTERPRETATION: Compared with conventional mechanical ventilation, use of venovenous ECMO in adults with severe acute respiratory distress syndrome was associated with reduced 60-day mortality. However, venovenous ECMO was also associated with a moderate risk of major bleeding. These findings have important implications surrounding decision making for management of severe acute respiratory distress syndrome at centres providing venovenous ECMO.
参考来源
- Munshi L, Walkey A, Goligher E, et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med. 2019. PMID: 30642776. doi:10.1016/S2213-2600(18)30452-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。